Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656231 | 0.78 | MAPT (0.36) | — | |
| SCHEMBL1443585 | 0.76 | TAAR1 (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL11047241 | 0.74 | DPP4 (0.39) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL29618975 | 0.74 | PSEN1 (0.40) | DPP4DPP8DPP7DPP9PSEN1 | |
| SCHEMBL1020440 | 0.74 | PSEN1 (0.40) | DPP4DPP8DPP7DPP9PSEN1 | |
| SCHEMBL8250509 | 0.74 | DPP4 (0.50) | DPP4DPP8DPP7DPP9PSEN1 | |
| SCHEMBL1443060 | 0.71 | TRPA1 (0.44) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL4718190 | 0.71 | MPO (0.44) | DPP4DPP8DPP7DPP9PSEN1 | |
| SCHEMBL439656 | 0.71 | DPP4 (0.56) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL441142 | 0.71 | DPP4 (0.56) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2473486-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | DPP4 2013/4885DPP8 2137/4885DPP7 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.